Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit ...

Controlling the dissolved oxygen in bioreactors sets the stage for developing new treatments for liver disease.

A research team behind a new study at the Hebrew University of Jerusalem has made an important breakthrough in understanding ...

Cancer has been described as "a wound that does not heal," implying that the immune system is unable to wipe out invading tumor cells. A new discovery confirms that a key molecule can reprogram immune ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Vasoactive Intestinal Peptide (VIP) is an intriguing neuropeptide with a wide range of potential biological impacts, primarily hypothesized in tissues, cells, and internal systems. Since its discovery ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

Recent research highlights a method that disrupts the interaction between two key proteins, offering a more precise and ...

Dendritic cells are poised to revolutionize oncology. This type of immune therapy shows effectiveness even in late-stage ...

Stem Cell Therapy Market Size Was Valued at USD 12.05 Billion in 2023, and is Projected to Reach USD 31.33 Billion by 2032, ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.